CVS enhances supports for patients taking GLP-1s

CVS Health is refining its weight management programs to provide better patient access and additional support for individuals taking GLP-1 medications. The company announced on Wednesday that its pharmacies offer all FDA-approved GLP-1 medications through insurance or cash-pay options. To better cater to patients taking Zepbound and Fazeayo, CVS will collaborate with Eli Lilly to incorporate a new touchpoint within its app.

By the end of the fourth quarter, eligible patients will be able to access transparent pricing information, including cash-pay costs, through the app and schedule in-store pickup for these GLP-1 medications.

This initiative builds upon CVS's existing partnership with Novo to dispense oral and injectable Wegovy, solidifying CVS Pharmacy as a convenient and affordable destination for all FDA-approved GLP-1 medications. Additionally, CVS is implementing enhanced pharmacy supports to facilitate patient adherence to these medications. The company will introduce new online visits with MinuteClinic, priced at $29, to evaluate patients for GLP-1s, with clinicians prescribing the drugs when appropriate.

CVS's pharmacists are regarded as a key differentiator in their approach to weight management and GLP-1 support. These healthcare professionals serve as trusted clinicians for patients, assisting with managing side effects, addressing questions, and fostering adherence. As the Medicare bridge program matures, offering coverage for these drugs to seniors, these services will become increasingly valuable.

This strategy aligns with CVS's broader objective to streamline the patient and consumer experience. CEO David Joyner highlighted that the company's work with GLP-1s exemplifies how they can integrate their assets to address consumer needs. CVS Health raised its guidance for the year, surpassing Wall Street analyst expectations in the second quarter.

The company reported near $3 billion in profit and $106.1 billion in revenue, both exceeding forecasts. This follows a strong first half of the year, with profits at $5.9 billion and revenue at $206.5 billion, both surpassing the previous year's figures of $2.8 billion in profit and $193.5 billion in revenue.